Khoja L. et al. (2017) reported that colitis, hypophysitis, and rash were more commonly associated with anti-CTLA-4 treatment, while pneumonitis, hypothyroidism, arthralgia, and vitiligo developed following treatment with anti-PD-1 antibodies [16]. This evidence concerns the gene PDCD1 and hypophysitis.